There are key steps to take that can ensure equitable access to pegcetacoplan, explained Carla Nester, MD, MSA, FASN, who also highlighted remaining questions on long-term outcomes, safety, and pediatric use.
Carla Nester, MD, MSA, FASN
Advertisement
Carla Nester, MD, MSA, FASN, has been in practice for 18 years, and is a pediatric and adult nephrologist at the University of Iowa Stead Family Children's Hospital, where she specializes in compliment-mediated glomerular diseases.
Articles by Carla Nester, MD, MSA, FASN
This approval offers a promising new targeted treatment for patients aged 12 and older with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), according to Carla Nester, MD, MSA, FASN, addressing a critical gap left by broad immunosuppressive therapies.
Iptacopan targets one of the major proteins involved in the enzymes of the alternative pathway of complement, explains Carla Nester, MD, of Stead Family Children's Hospital.
Carla Nester, MD, MSA, FASN, is coinvestigator for the ongoing APPEAR-C3G trial (NCT04817618), data from which were used to support the FDA’s recent approval of iptacopan (Fabhalta; Novartis) in complement 3 glomerulopathy (C3G).
Advertisement
Latest Updated Articles
Pegcetacoplan Offers Promising New Treatment Approach for Patients Aged 12 and Older With C3G, Primary IC-MPGN: Carla Nester, MD, MSA, FASNPublished: August 1st 2025 | Updated:
- Ensuring Access to Pegcetacoplan Requires Updated Guidelines, Education, and Distribution Solutions: Carla Nester, MD, MSA, FASN
Published: August 4th 2025 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Guidelines for Bronchiectasis Highlight Multiple Treatment Methods
2
Many US Health Care Workers Face Poverty, Food Insecurity, and Housing Instability
3
Combination Therapy Proves More Effective in NSCLC Compared With Chemotherapy
4
Ongoing COVID-19 Circulation Linked to Increases in Health-Related Work Absences, Workforce Exits
5
